Current approaches to the molecular and physiological basis of cystic fibrosis
- PMID: 2479269
- DOI: 10.1097/00000441-198911000-00012
Current approaches to the molecular and physiological basis of cystic fibrosis
Abstract
Cystic fibrosis (CF) is the most common disease caused by a single gene abnormality within the caucasian population. Its severity of expression in homozygotes varies widely, and the disease involves multiple organ systems. During the past few years, major advances in CF research have been made. These advances have occurred primarily in the fields of physiology and molecular genetics. As a result of these advances, it is now generally accepted that the basic defect in CF is the inability of an epithelial chloride channel to respond to adrenergic stimulation in affected organs. The recent major breakthrough in CF research is the localization of the CF gene and identification of the mutation responsible for the majority of cases of CF. In this article, the evidence which has led to this conclusion, as well as possible mechanisms by which a mutation in a single codon can produce the CF defects are reviewed. Finally, new approaches to the characterization of the CF gene by complementation of the defect in immortal cell lines displaying the transport phenotype associated with CF are discussed.
Similar articles
-
The cystic fibrosis defect approached from different angles--new perspectives on the gene, the chloride channel, diagnosis and therapy.Eur J Pediatr. 1990 Jul;149(10):670-7. doi: 10.1007/BF01959519. Eur J Pediatr. 1990. PMID: 1698628 Review.
-
Expression of normal and cystic fibrosis phenotypes by continuous airway epithelial cell lines.Am J Physiol. 1990 Dec;259(6 Pt 1):L496-505. doi: 10.1152/ajplung.1990.259.6.L496. Am J Physiol. 1990. PMID: 1701980
-
A clue to the basic defect in cystic fibrosis from cloning the CF antigen gene.Nature. 1987 Apr 9-15;326(6113):614-7. doi: 10.1038/326614a0. Nature. 1987. PMID: 3561500
-
[Molecular biological analysis of cystic fibrosis--a model example for the strategy of "reverse genetics"].Padiatr Grenzgeb. 1992;31(2):73-95. Padiatr Grenzgeb. 1992. PMID: 1284810 Review. German.
-
Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.Ther Adv Respir Dis. 2015 Dec;9(6):313-26. doi: 10.1177/1753465815601934. Epub 2015 Sep 28. Ther Adv Respir Dis. 2015. PMID: 26416827 Review.
Cited by
-
Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients.Infect Immun. 2006 Aug;74(8):4708-14. doi: 10.1128/IAI.02066-05. Infect Immun. 2006. PMID: 16861658 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous